| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8807261 | Current Research in Translational Medicine | 2018 | 4 Pages |
Abstract
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Caroline Lonez, Alain Hendlisz, Leila Shaza, Philippe Aftimos, Michaël Vouche, Vincent Donckier, Jean-Pascal H. Machiels, Marc Van Den Eynde, Jean-Luc Canon, Javier Carrasco, Kunle Odunsi, Solmaz Sahebjam, Sylvie Rottey, Nathalie Braun, Bikash Verma,